Erik Helgstrand
- Co-authors
- Alfons MisiornyB. ErikssonJan Olof NorenS. StridhGöran SteningBo ÖbergAlf LarssonLennart Philipson
- Topics
- HIV/AIDS drug development and treatment (5 papers)Synthesis and Characterization of Heterocyclic Compounds (4 papers)Biochemical and Molecular Research (3 papers)
- Partner nations
- Sweden
In The Last Decade
Erik Helgstrand
19 papers receiving 539 citations
Peers
Comparison fields: 5 of 72
- Epidemiology 315
- Molecular Biology 210
- Infectious Diseases 210
- Organic Chemistry 113
- Immunology 72
Countries citing papers authored by Erik Helgstrand
This map shows the geographic impact of Erik Helgstrand's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Helgstrand with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Helgstrand more than expected).
Fields of papers citing papers by Erik Helgstrand
This network shows the impact of papers produced by Erik Helgstrand. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Helgstrand. The network helps show where Erik Helgstrand may publish in the future.
Co-authorship network of co-authors of Erik Helgstrand
This figure shows the co-authorship network connecting the top 25 collaborators of Erik Helgstrand. A scholar is included among the top collaborators of Erik Helgstrand based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Helgstrand. Erik Helgstrand is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 52 | |
| 3 | Inhibition of hepatitis B Dane particle DNA polymerase activity by pyro-phosphate analogs. | 13 |
| 4 | 68 | |
| 5 | 19 | |
| 6 | Experimental studies on the antiherpetic agent phosphonoformic acid. | 5 |
| 7 | 18 | |
| 8 | 12 | |
| 9 | 175 | |
| 10 | 215 | |
| 11 | Potential hypolipidemic agents. V. Syntheses of some new 3-substituted pyridines. Effects on noradrenaline-stimulated free fatty acid mobilization. | 1 |
| 12 | Potential hypolipidemic agents. I. Syntheses of esters related to 5-fluoro- and 5-chloronicotinic acid and the corresponding alcohols. Effects on noradrenaline-stimulated free fatty acid mobilization. | 1 |
| 13 | 2 | |
| 14 | Potential hypolipidemic agents. 3. Heterocyclic compounds affecting free fatty acid mobilization in vivo. | 1 |
| 15 | 3 | |
| 16 | 16 | |
| 17 | 2 | |
| 18 | 1 | |
| 19 | 2 | |
| 20 | 1 |
About Erik Helgstrand
Erik Helgstrand is a scholar working on Pharmaceutical Science, Organic Chemistry and Infectious Diseases, having authored 20 papers that have together received 607 indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (5 papers), Synthesis and Characterization of Heterocyclic Compounds (4 papers) and Biochemical and Molecular Research (3 papers). The work is most often cited by research in Infectious Diseases (210 citations), Virology (46 citations) and Epidemiology (315 citations). Erik Helgstrand has collaborated with scholars based in Sweden. Frequent co-authors include Alfons Misiorny, B. Eriksson, Jan Olof Noren, S. Stridh, Göran Stening, Bo Öberg, Alf Larsson, Lennart Philipson, K Stenberg and Nils Gunnar Johansson. Their work appears in journals such as Science, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.